https://medical.vorbio.com/publication/ 2026-06-23T18:40:37+00:00 https://medical.vorbio.com/publication/a-phase-3-study-to-evaluate-the-efficacy-and-safety-of-telitacicept-in-patients-with-generalized-myasthenia-gravis-trial-design-update/ 2026-06-22T21:05:20+00:00 https://medical.vorbio.com/publication/telitacicept-as-a-novel-baff-april-targeted-therapy-for-sjogrens-disease/ 2026-06-22T21:08:17+00:00 https://medical.vorbio.com/publication/global-phase-3-study-to-evaluate-the-efficacy-and-safety-of-telitacicept-in-patients-with-generalized-myasthenia-gravis-rememg/ 2026-06-22T21:09:52+00:00 https://medical.vorbio.com/publication/a-phase-3-randomized-double-blind-placebo-controlled-study-with-an-open-label-extension-period-to-evaluate-the-efficacy-and-safety-of-telitacicept-in-patients-with-generalized-myasthenia-gravis-up/ 2026-06-22T21:15:13+00:00 https://medical.vorbio.com/publication/efficacy-and-safety-of-telitacicept-in-patients-with-generalized-myasthenia-gravis-results-of-a-phase-3-study/ 2026-06-22T21:26:39+00:00 https://medical.vorbio.com/publication/efficacy-and-safety-of-telitacicept-in-participants-with-sjogrens-disease-results-from-a-multicenter-randomized-double-blind-placebo-controlled-phase-3-clinical-study/ 2026-06-22T21:29:37+00:00 https://medical.vorbio.com/publication/efficacy-and-safety-of-telitacicept-in-patients-with-generalized-myasthenia-gravis-results-from-a-phase-3-study/ 2026-06-23T18:40:37+00:00